Search

Your search keyword '"Guillemin, Francis"' showing total 1,918 results
Start Over Author "Guillemin, Francis"
1,918 results on '"Guillemin, Francis"'

204. Behavioural risk patterns in adolescents with excess weight participating in the PRALIMAP-INÈS trial.

Author

Julia, Chantal, Omorou, Abdou, Lecomte, Edith, Langlois, Johanne, Touvier, Mathilde, Hercberg, Serge, Briançon, Serge, Kesse-Guyot, Emmanuelle, and Guillemin, Francis

Subjects
SEDENTARY behavior, HIERARCHICAL clustering (Cluster analysis), SOCIAL status, TEENAGERS, ALCOHOL drinking
Abstract

Objective: To investigate clustering of risk behaviours in adolescents with excess weight. Design: Cross-sectional analysis of baseline data from the PRALIMAP-INÈS trial. Information on food frequency consumption (fruit, vegetables, sugary products and beverages), physical activity, sedentary behaviour (week and weekend days), smoking and alcohol consumption (current frequency and intoxication episodes) and socio-demographic data was collected using self-reported questionnaires. Behavioural risk factors were entered as categorical variables in a two-step clustering procedure: multiple correspondence analysis followed by hierarchical clustering. Associations between cluster membership and socio-demographic variables were investigated using multivariable multinomial logistic regression. Setting: French PRALIMAP-INÈS trial. Participants: Adolescents with excess weight. Results: A total of 1391 participants (13–18 years old, 58·2 % female) were included in the analysis, which resulted in the identification of four groups of participants, including, respectively, 543 (39·0 %), 373 (26·8 %), 246 (17·7 %) and 229 (16·5 %) participants. Clusters 1 and 4 showed associations of rather healthy behaviours (high physical activity and low consumption of sugary products; high consumption of fruit and vegetables, respectively), while clusters 2 and 3 showed associations of rather unhealthy behaviours (high sedentary behaviour and low consumption of fruit and vegetables; smoking and alcohol consumption, respectively). Both social status and family structure were associated with cluster membership. Conclusions: Risk behaviour patterns in adolescents with excess weight were clustered in both healthier and less healthy ways, with a complex interplay with socio-demographic factors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

205. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.

Author

Gwinnutt, James M., Wieczorek, Maud, Balanescu, Andra, Bischoff-Ferrari, Heike A., Boonen, Annelies, Cavalli, Giulio, de Souza, Savia, de Thurah, Annette, Dorner, Thomas E., Moe, Rikke Helene, Putrik, Polina, Rodríguez-Carrio, Javier, Silva-Fernández, Lucía, Stamm, Tanja, Walker-Bone, Karen, Welling, Joep, Zlatković-Švenda, Mirjana I., Guillemin, Francis, and Verstappen, Suzanne M. M.

Published
2023
Full Text
View/download PDF

206. Early Acceptability of a Mobile App for Contact Tracing During the COVID-19 Pandemic in France: National Web-Based Survey

Author

Touzani, Rajae, Schultz, Emilien, Holmes, Seth, Vandentorren, Stéphanie, Arwidson, Pierre, Guillemin, Francis, Rey, Dominique, Rouquette, Alexandra, Bouhnik, Anne-Déborah, Mancini, Julien, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), Institut d'Etudes Avancées [AMU] (IMéRA), Aix Marseille Université (AMU), University of California [Berkeley], University of California, Santé publique France - French National Public Health Agency [Saint-Maurice, France], Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Biostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] (BiosTIC ), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Recherche pour le Développement (IRD)-Université Paris Cité (UPCité), University of California [Berkeley] (UC Berkeley), University of California (UC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), and Malbec, Odile

Subjects
Internet, Original Paper, SARS-CoV-2, [SDV]Life Sciences [q-bio], HLS19, public health, COVID-19, health care disparities, Middle Aged, Mobile Applications, contact tracing, [SDV] Life Sciences [q-bio], mobile app, mental disorders, Humans, France, Pandemics
Abstract

International audience; Background: Several countries have implemented mobile apps in an attempt to trace close contacts of patients with COVID-19 and, in turn, reduce the spread of SARS-CoV-2. However, the effectiveness of this approach depends on the adherence of a large segment of the population.Objective: The aims of this study were to evaluate the acceptability of a COVID-19 contact tracing mobile app among the French population and to investigate the barriers to its use.Methods: The Health Literacy Survey 2019 questioned 1003 people in France during the COVID-19 pandemic on the basis of quota sampling. The survey collected sociodemographic characteristics and health literacy data, as well as information on participants' communication with caregivers, trust in institutions, and COVID-19 knowledge and preventive behaviors. The acceptability of a mobile app for contact tracing was measured by a single question, the responses to which were grouped into three modalities: app-supporting, app-willing, and app-reluctant. Multinomial logistic regression analysis was performed to identify the factors associated with the acceptability of a mobile app during the COVID-19 pandemic.Results: Only 19.2% (193/1003) of all participants were app-supporting, whereas half of them (504/1003, 50.3%) were reluctant. The factors associated with willingness or support toward the contact tracing app included lower financial deprivation (app-willing: adjusted odds ratio [aOR] 0.8, 95% CI 0.69-0.93; app-supporting: aOR 0.7, 95% CI 0.58-0.84) and higher perceived usefulness of using a mobile app to send completed health questionnaires to doctors (app-willing: aOR 2.3, 95% CI 1.70-3.26; app-supporting: aOR 3.1, 95% CI 2.04-4.82). Furthermore, the likelihood of supporting the mobile app increased with age over 60 years (aOR 1.9, 95% CI 1.13-3.22), trust in political representatives (aOR 2.7, 95% CI 1.72-4.23), feeling concerned about the pandemic situation (aOR 2.2, 95% CI 1.47-3.32), and knowledge about the transmission of COVID-19 (aOR 2.0, 95% CI 1.39-2.96).Conclusions: The most socioeconomically precarious people, who are at a higher risk of SARS-CoV-2 infection, are also the most reluctant to using a contact tracing mobile app. Therefore, optimal adherence can only be effective with a targeted discourse on public health benefits to adopt such an app, which should be combined with a reduction in inequalities by acting on structural determinants.

Published
2021

207. Comparative effectiveness of dimethyl fumarate in multiple sclerosis

Author

Bosco‐Lévy, Pauline, primary, Debouverie, Marc, additional, Brochet, Bruno, additional, Guillemin, Francis, additional, Louapre, Céline, additional, Maillart, Elisabeth, additional, Heinzlef, Olivier, additional, Lignot, Séverine, additional, Diez, Pauline, additional, Abouelfath, Abdelilah, additional, Lassalle, Régis, additional, Blin, Patrick, additional, and Droz‐Perroteau, Cécile, additional

Published
2021
Full Text
View/download PDF

209. Recherche sur la fin de vie, la nécessité d’un consensus : premiers résultats

Author

Bernard, Cécile, primary, Hamidou, Zeinab, additional, Billa, Oumar, additional, Dany, Lionel, additional, Amouroux-Gorsse, Valérie, additional, Dubois, Lise, additional, Gallois, Marion, additional, de Larivière, Emmanuel, additional, Lamie, Séverine, additional, Peyrat-Apicella, Delphine, additional, Vezy, Pierre, additional, Aubry, Régis, additional, Guillemin, Francis, additional, Dabakuyo-Yonli, Sandrine, additional, and Auquier, Pascal, additional

Published
2021
Full Text
View/download PDF

210. Web-based and machine learning approaches for identification of patient-reported outcomes in inflammatory bowel disease

Author

Ricci, Laetitia, primary, Toussaint, Yannick, additional, Becker, Justine, additional, Najjar, Hiba, additional, Renier, Alix, additional, Choukour, Myriam, additional, Buisson, Anne, additional, Devos, Corinne, additional, Epstein, Jonathan, additional, Peyrin Biroulet, Laurent, additional, and Guillemin, Francis, additional

Published
2021
Full Text
View/download PDF

212. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study

Author

Zuily, Stéphane, de Laat, Bas, Mohamed, Shirine, Kelchtermans, Hilde, Shums, Zakera, Albesa, Roger, Norman, Gary L., Lamboux-Matthieu, Claire, Rat, Anne-Christine, Ninet, Jacques, Magy-Bertrand, Nadine, Pasquali, Jean-Louis, Lambert, Marc, Lorcerie, Bernard, Kaminsky, Pierre, Guillemin, Francis, Regnault, Véronique, and Wahl, Denis

Published
2015
Full Text
View/download PDF

215. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology

Author

Buch, Maya H, Silva-Fernandez, Lucia, Carmona, Loreto, Aletaha, Daniel, Christensen, Robin, Combe, Bernard, Emery, Paul, Ferraccioli, Gianfranco, Guillemin, Francis, Kvien, Tore K, Landewe, Robert, Pavelka, Karel, Saag, Kenneth, Smolen, Josef S, Symmons, Deborah, van der Heijde, Désirée, Welling, Joep, Wells, George, Westhovens, Rene, Zink, Angela, and Boers, Maarten

Published
2015
Full Text
View/download PDF

217. Prevalence of impairments, disabilities, handicaps and quality of life in the general population: a review of recent literature

Author

Barbotte Eric, Guillemin Francis, and Chau Nearkasen

Subjects
Disabled persons, Prevalence, Quality of life, Review literature, Public aspects of medicine, RA1-1270
Abstract

OBJECTIVE: To determine the prevalence rates of morbidity in the general population through bibliographic research. METHODS: Articles relating to impairment, disability, handicap, quality of life and their prevalence in the general population, published between January 1990 and March 1998, were selected on the MEDLINE database. FINDINGS: The 20 articles retained out of 433 used 41 different indicators. Indicators of impairment, disability, handicap and low quality of life showed prevalence rates of 0.1-92%, 3.6-66%, 0.6-56% and 1.8-26% respectively, depending on age and the accuracy of indicators. The heterogeneity of the conceptual framework and insufficient recognition of the importance of indicator accuracy, the age factor and the socioeconomic characteristics of the studied populations impede reliable international comparison. CONCLUSION: Further standardization of indicators is therefore required. The revision of the International Classification of Impairments, Disabilities and Handicaps may make it possible to resolve some of the difficulties encountered.

Published
2001

218. Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke

Author

Almekhlafi, Mohammed, Goyal, Mayank, Dippel, Diederik, Majoie, Charles, Campbell, Bruce, Muir, Keith, Demchuk, Andrew, Bracard, Serge, Guillemin, Francis, Jovin, Tudor, Mitchell, Peter, White, Philip, Hill, Michael, Brown, Scott, Saver, Jeffrey, Berkhemer, Olvert, Fransen, Puck, Beumer, Debbie, Van Den Berg, Lucie, Lingsma, Hester, Yoo, Albert, Schonewille, Wouter, Vos, Jan, Nederkoorn, Paul, Wermer, Marieke, Van Walderveen, Marianne, Staals, Julie, Hofmeijer, Jeannette, Van Oostayen, Jacques, Lycklama À Nijeholt, Geert, Boiten, Jelis, Brouwer, Patrick, Emmer, Bart, De Bruijn, Sebastiaan, Van Dijk, Lukas, Kappelle, L, Lo, Rob, Van Dijk, Ewoud, de Vries, Joost, De Kort, Paul, Van Rooij, Willem, Van Den Berg, Jan, Van Hasselt, Boudewijn, Aerden, Leo, Dallinga, René, Visser, Marieke, Bot, Joseph, Vroomen, Patrick, Eshghi, Omid, Schreuder, Tobien, Heijboer, Roel, Keizer, Koos, Tielbeek, Alexander, Den Hertog, Heleen, Gerrits, Dick, Van Den Berg-Vos, Renske, Karas, Giorgos, Steyerberg, Ewout, Flach, H, Marquering, Henk, Sprengers, Marieke, Jenniskens, Sjoerd, Beenen, Ludo, Van Den Berg, René, Koudstaal, Peter, Van Zwam, Wim, Roos, Yvo, van der Lugt, Aad, Van Oostenbrugge, Robert, Menon, Bijoy, Eesa, Muneer, Rempel, Jeremy, Thornton, John, Roy, Daniel, Willinsky, Robert, Sapkota, Biggya, Dowlatshahi, Dar, Frei, Donald, Kamal, Noreen, Montanera, Walter, Poppe, Alexandre, Ryckborst, Karla, Silver, Frank, Shuaib, Ashfaq, Tampieri, Donatella, Williams, David, Bang, Oh, Baxter, Blaise, Burns, Paul, Choe, Hana, Heo, Ji-Hoe, Holmstedt, Christine, Jankowitz, Brian, KELLY, Michael, Linares, Guillermo, Mandzia, Jennifer, Shankar, Jai, Sohn, Sung-Il, Swartz, Richard, Coutts, Shelagh, Smith, Eric, Morrish, William, Weill, Alain, Subramaniam, Suresh, Mitha, Alim, Wong, John, Lowerison, Mark, Sajobi, Tolulope, Bonafe, Alain, Diener, Hans, Levy, Elad, Pereira, Vitor, Albers, Gregory, Cognard, Christophe, Cohen, David, Hacke, Werner, Jansen, Olav, Mattle, Heinrich, Nogueira, Raul, Siddiqui, Adnan, Yavagal, Dileep, Devlin, Thomas, Lopes, Demetrius, Reddy, Vivek, du Mesnil de Rochemont, Richard, Singer, Oliver, Jahan, Reza, Kleinig, Timothy, Dewey, Helen, Churilov, Leonid, Yassi, Nawaf, Yan, Bernard, Dowling, Richard, Parsons, Mark, Oxley, Thomas, Wu, Teddy, Brooks, Mark, Simpson, Marion, Miteff, Ferdinand, Levi, Christopher, Krause, Martin, Harrington, Timothy, Faulder, Kenneth, Steinfort, Brendan, Priglinger, Miriam, Ang, Timothy, Scroop, Rebecca, Barber, Philip, McGuinness, Ben, Wijeratne, Tissa, Phan, Thanh, Chong, Winston, Chandra, Ronil, Bladin, Christopher, Badve, Monica, Rice, Henry, de Villiers, Laetitia, Ma, Henry, Desmond, Patricia, Donnan, Geoffrey, Davis, Stephen, Chamorro, Angel, Cobo, Erik, De Miquel, María, Molina, Carlos, Rovira, Alex, San Román, Luis, Serena, Joaquín, Abilleira, Sonia, Ribó, Marc, Millán, Mònica, Urra, Xabier, Cardona, Pere, López-Cancio, Elena, Tomasello, Alejandro, Castaño, Carlos, Blasco, Jordi, Aja, Lucía, Dorado, Laura, Quesada, Helena, Rubiera, Marta, Hernandez-Pérez, María, von Kummer, Rüdiger, Gallofré, Miquel, Dávalos, Antoni, Ford, Gary, Messow, Claudia-Martina, Ford, Ian, Murray, Alicia, Clifton, Andrew, Brown, Martin, Madigan, Jeremy, Lenthall, Rob, Robertson, Fergus, Dixit, Anand, Cloud, Geoffrey, Wardlaw, Joanna, Freeman, Janet, Ducrocq, Xavier, Mas, Jean, Soudant, Marc, Oppenheim, Catherine, Moulin, Thierry, University of Calgary, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Department of Radiology and Nuclear Medicine [Amsterdam], VU University Medical Center [Amsterdam], University of Melbourne, University of Glasgow, Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), The Royal Melbourne Hospital, Newcastle University [Newcastle], Altair Development, David Geffen School of Medicine [Los Angeles], University of California [Los Angeles] (UCLA), and University of California-University of California

Subjects
[INFO.INFO-IM]Computer Science [cs]/Medical Imaging, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; The benefits of endovascular thrombectomy (EVT) are time dependent. Prior studies may have underestimated the time-benefit association because time of onset is imprecisely known. OBJECTIVE To assess the lifetime outcomes associated with speed of endovascular thrombectomy in patients with acute ischemic stroke due to large-vessel occlusion (LVO). DATA SOURCES PubMed was searched for randomized clinical trials of stent retriever thrombectomy devices vs medical therapy in patients with anterior circulation LVO within 12 hours of last known well time, and for which a peer-reviewed, complete primary results article was published by August 1, 2020.

Published
2021

219. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort

Author

Tubiana, Sarah, Burdet, Charles, Houhou, Nadhira, Thy, Michael, Manchon, Pauline, Blanquart, François, Charpentier, Charlotte, Guedj, Jérémie, Alavoine, Loubna, Behillil, Sylvie, Leclercq, Anne, Lucet, Jean-Christophe, Yazdanpanah, Yazdan, Attia, Mikaël, Demeret, Caroline, Rose, Thierry, Bielicki, Julia Anna, Bruijning-Verhagen, Patricia, Goossens, Herman, Descamps, Diane, van der Werf, Sylvie, Lina, Bruno, Duval, Xavier, Abad, Fanny, Abry, Dominique, Allain, Jean-Sébastien, Amiel-Taieb, Karline, Audoin, Pierre, Augustin, Shana, Ayala, Sandrine, Bansard, Hélène, Bertholon, Fréderique, Boissel, Nolwenn, Botelho-Nevers, Elisabeth, Bouiller, Kévin, Bourgeon, Marilou, Boutrou, Mathilde, Brick, Lysiane, Bruneau, Léa, Caumes, Eric, Chabouis, Agnès, Chan Thien, Eric, Chirouze, Catherine, Coignard, Bruno, Costa, Yolande, Costenoble, Virginie, Cour, Sylvie, Cracowski, Claire, Cracowski Jean, Luc, Deplanque, Dominique, Dequand, Stéphane, Desille-Dugast, Mireille, Desmarets, Maxime, Detoc, Maelle, Dewitte, Marie, Djossou, Felix, Ecobichon, Jean-Luc, Elrezzi, Elise, Faurous, William, Fortuna, Viviane, Fouchard, Julie, Gantier, Emilie, Gautier, Céline, Gerardin, Patrick, Gerset, Sandrine, Gilbert, Marie, Gissot, Valérie, Guillemin, Francis, Hartard, Cédric, Hazevis, Béatrice, Hocquet, Didier, Hodaj, Enkelejda, Ilic-Habensus, Emila, A, Jeudy, Jeulin, Helene, Kane, Maty, Kasprzyk, Emmanuelle, Kikoine, John, Laine, Fabrice, Laviolle, Bruno, Lebeaux, David, Ledru, Eric, Lefevre, Benjamin, Legoas, Carole, Legrand, Amélie, Legrand, Karine, Lehacaut, Jonathan, Lehur, Claire, Lemouche, Dalila, Lepiller, Quentin, Lepuil, Sévérine, Letienne, Estelle, Lucarelli, Aude, Madeline, Isabelle, Maillot, Adrien, Malapate, Catherine, Malvy, Denis, Mandic, Milica, Marty-Quinternet, Solène, Meghadecha, Mohamed, Mergeay-Fabre, Mayka, Mespoulhe, Pauline, Meunier, Alexandre, Migaud, Maria-Claire, Motiejunaite, Justina, Nathalie, Gay, Nguyen, Duc, Oubbea, Soumaya, Pagadoy, Maïder, Paris, Adeline, Paris, Christophe, Payet, Christine, Peiffer-Smadja, Nathan, Perez, Lucas, Perreau, Pauline, Pierrez, Nathalie, Pistone, Thierry, Postolache, Andreea, Rasoamanana, Patrick, Reminiac, Cécile, Rexah, Jade, Roche-Gouanvic, Elise, Rousseau, Alexandra, Schoemaecker, Betty, Simon, Sandrine, Soler, Catherine, Somers, Stéphanie, Sow, Khaly, Tardy, Bernard, Terzian, Zaven, Tournier, Anne, Tyrode, Sandrine, Vauchy, Charline, Verdon, Renaud, Vernet, Pauline, Vignali, Valérie, Waucquier, Nawal, Do Thi Thu, Huong, Laouénan, Cédric, Mentre, France, Pauline, Manchon, Dechanet, Aline, Letrou, Sophie, Quintin, Caroline, Frezouls, Wahiba, Le Hingrat, Quentin, Damond, Florence, Descamps, Dianes, Visseaux, Benoit, Vabret, Astrid, Bouscambert, Maud, Gaillanne, Laurence, Benmalek, Nabil, Attia, Mikael, Barbet, Marion, Petres, Stéphane, Escriou, Nicolas, Goyard, Sophie, Kafif, Ouifiya, Piquard, Valentine, Mailles, Alexandra, Simondon, Anne, Dreyere, Marion, Morel, Bruno, Vesval, Thiphaine, Amat, Karine, Ammour, Douae, Aqourras, Khadija, Couffin-Cadiergues, Sandrine, Delmas, Christelle, Desan, Vristi, Jean, Michel Doute, Esperou, Hélène, Hendou, Samia, Kouakam, Christelle, Le Meut, Guillaume, Lemestre, Soizic, Leturque, Nicolas, Marcoul, Emmanuelle, Nguefang, Solange, Roufai, Layidé, Abel, Laurent, Caillat-Zucman, Sophie, Study Group, Covcontact, Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Hôpital Beaujon [AP-HP], Physique des fonctions biologiques / Physics of Biological Functions, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Biologie Cellulaire des Lymphocytes - Lymphocyte Cell Biology, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), St George's, University of London, University Children’s Hospital Basel = Hôpital pédiatrique universitaire des deux Bâle [Bâle, Suisse] (UKBB), University Medical Center [Utrecht], Universiteit Antwerpen = University of Antwerpen [Antwerpen], Virology and human respiratory Pathologies - Virology and human respiratory Pathologies (VirPath), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR - laboratoire associé), Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), ANR-20-COVI-0002,CORaDiag,COVID 19 Rapid diagnosis test (development and clinical validation in 7 weeks)(2020), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Microbiology (medical), medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Health Personnel, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Pneumonia, Viral, Sars-cov-2, Betacoronavirus, 03 medical and health sciences, Health personnel, 0302 clinical medicine, High-risk exposure, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Personal protective equipment, medicine, Humans, Risk exposure, Transmission, 030212 general & internal medicine, Letter to the Editor, Pandemics, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, 030306 microbiology, Transmission (medicine), business.industry, COVID-19, 3. Good health, Infectious Diseases, Cohort, Emergency medicine, In-hospital workers, Human medicine, Coronavirus Infections, business
Abstract

International audience

Published
2021
Full Text
View/download PDF

220. Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives

Author

Marcoul Emmanuelle, Benoit Visseaux, Minh Patrick Lê, Alphonsine Diouf, Mergeay-Fabre Mayka, Kasprzyk Emmanuelle, Hazevis Beatrice, Houhou Nadhira, Christophe Choquet, Laviolle Bruno, Benedicte Rossignol, Verdon Renaud, Aqourras Khadija, Bourgeon Marilou, Lehur Claire, Ikram Houas, Ventzislava Petrov-Sanchez, Jeremie Guedj, Aurelie Veislinger, Amina Meziane, Brick Lysiane, Salma Jaafoura, Alexandre Hoctin, Visseaux Benoit, Oriane Puéchal, Alavoine Loubna, Denis Malvy, Gautier Celine, Letienne Estelle, Djossou Felix, Amiel-Taieb Karline, Esperou Helene, Thy Michael, Alpha Diallo, Bertholon Frederique, Sow Khaly, Boutrou Mathilde, Somers Stephanie, Tardy Bernard, Descamps Dianes, Rose Thierry, Morgane Gilg, Lucarelli Aude, Kikoine John, Charles Burdet, Barbet Marion, Kafif Ouifiya, Yazdan Yazdanpanah, Perez Lucas, Justine Pages, Laurent Abel, Florence Damond, Kouakam Christelle, Guillemin Francis, Dominique Deplanque, Marie Pierre Debray, Camille Couffignal, Botelho-Nevers Elisabeth, Jean Sebastien Hulot, Desmarets Maxime, Meunier Alexandre, Legrand Amelie, Maillot Adrien, Marine Beluze, Hartard Cedric, Bansard Helene, Legoas Carole, Gantier Emilie, Ledru Eric, Noemie Mercier, Sylvie van der Werf, Philippine Eloy, Guillaume Lingas, Coralie Tardivon, Fouchard Julie, Dewitte Marie, Bruno Lina, Alexandra Coelho, Boissel Nolwenn, Demeret Caroline, Marty-Quinternet Solene, Cédric Laouénan, Nassima Si Mohammed, Meghadecha Mohamed, Reminiac Cecile, Isabelle Gorenne, Chabouis Agnes, Paris Adeline, Sabrina Kali, Pierrez Nathalie, Mathilde Desvallee, Cracowski Jean Luc, Nathan Peiffer-Smadja, Tournier Anne, Abry Dominique, Marina Esposito-Farese, Lucet Jean-Christophe, Tristan Gigante, Abad Fanny, Olivier Picone, Lefevre Benjamin, Soizic Le Mestre, Ecobichon Jean-Luc, Manuel Rosa-Calatrava, Morel Bruno, Leturque Nicolas, Nguyen Duc, Nathalie Gault, Simon Sandrine, Jade Ghosn, Letrou Sophie, Elrezzi Elise, Ilic-Habensus Emila, Hodaj Enkelejda, Quintin Caroline, Doute Jean Michel, Schoemaecker Betty, Escriou Nicolas, Francois Dubos, A. Jeudy, Gilles Peytavin, Nadhira Houhou-Fidouh, Aurelie Papadopoulos, Noemie Vanel, Aurélie Wiedemann, Vincent Enouf, Rasoamanana Patrick, Behillil Sylvie, Le Hingrat Quentin, Vernet Pauline, Eric D'Ortenzio, Couffin-Cadiergues Sandrine, Damond Florence, Rousseau Alexandra, Jimmy Mullaert, Lemestre Soizic, Cracowski Claire, Malapate Catherine, Hocquet Didier, Francois Teoule, Hervé Le Nagard, Krishna Bhavsar, Mandic Milica, Postolache Andreea, Yves Levy, Caroline Semaille, Perreau Pauline, Frezouls Wahiba, Malvy Denis, Bouscambert Maud, Nadège Néant, Soler Catherine, Dreyere Marion, Nabil Benmalek, Diane Descamps, Allain Jean-Sebastien, Gerardin Patrick, Lila Bouadma, Charlotte Charpentier, Roufai Layide, Caillat-Zucman Sophie, Sandrine Couffin-Cardiergues, Sylvie Behilill, François Angoulvant, Coignard Bruno, Marina Mambert, Petres Stephane, Jean-François Timsit, Dehbia Benkerrou, Coralie Khan, Goyard Sophie, Motiejunaite Justina, Le Meut Guillaume, Burdet Charles, Christelle Paul, Catherine Chirouze, Pagadoy Maider, Hugo Mouquet, Hendou Samia, Fortuna Viviane, Dechanet Aline, Claire Andrejak, Marion Schneider, Claire Levy-Marchal, Christelle Tual, Olivier Terrier, Gerset Sandrine, J.-C. Lucet, Ammour Douae, Quentin Le Hingrat, Madeline Isabelle, Piquard Valentine, Costenoble Virginie, Paris Christophe, Lepiller Quentin, Manuel Etienne, Vignali Valerie, Oubbea Soumaya, Kane Maty, Hélène Espérou, François-Xavier Lescure, Desan Vristi, Vauchy Charline, Francois Bompart, Simondon Anne, Xavier Duval, Delphine Bachelet, Tyrode Sandrine, Rexah Jade, Bruneau Lea, Carine Roy, Gilbert Marie, Amat Karine, Augustin Shana, Gissot Valerie, Lehacaut Jonathan, Do Thi Thu Huong, Antoine Khalil, Marie Capucine Tellier, Pauline Manchon, Ouifiya Kafif, Bouiller Kevin, Jeulin Helene, Faurous William, Tubiana Sarah, Cour Sylvie, Detoc Maelle, Van Der Werf Sylvie, Mailles Alexandra, Audoin Pierre, Nguefang Solange, Mespoulhe Pauline, Caumes Eric, Alexandre Gaymard, Pistone Thierry, Laouenan Cedric, Delmas Christelle, Lepuil Severine, Ayala Sandrine, Lemouche Dalila, Dequand Stephane, Céline Dorival, Lina Bruno, Minerva Cervantes-Gonzalez, Duval Xavier, Costa Yolande, Leclercq Anne, Vabret Astrid, Theo Trioux, Samira Laribi, Roche-Gouanvic Elise, Houria Ichou, Deplanque Dominique, Isabelle Hoffmann, Marion Noret, Benmalek Nabil, Gaillanne Laurence, Mélanie Bertine, Lysa Tagherset, Peiffer-Smadja Nathan, Migaud Maria-Claire, Waucquier Nawal, Desille-Dugast Mireille, Nadia Ettalhaoui, Sarah Tubiana, Payet Christine, Romain Basmaci, Laine Fabrice, Attia Mikael, Patrick Rossignol, Charlene Da Silveira, Legrand Karine, Florentia Kaguelidou, Chirouze Catherine, Chan Thien Eric, Lebeaux David, Maude Bouscambert, Vesval Thiphaine, Charpentier Charlotte, Terzian Zaven, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP), Qiagen, BioMérieux, Gilead, Theratechnologie, Hologic, ViiV Healthcare, Abbvie, BMS, J&J, Pfizer, Beckton Dickinson, REACTing, 20-0424, Ministry of Health, ANRS, AAZ, Inserm, Sanofi Pasteur, Da Volterra, Biomerieux, Mylan, MSD, Medimune, Gilead Sciences, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Jonchère, Laurent

Subjects
0301 basic medicine, Microbiology (medical), Serum, medicine.medical_specialty, Saliva, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], 030106 microbiology, Antigenemia, Gastroenterology, 03 medical and health sciences, Plasma, 0302 clinical medicine, Antigen, Internal medicine, Medicine, Sampling (medicine), 030212 general & internal medicine, Symptom onset, Diagnostic, business.industry, SARS-CoV-2, COVID-19, General Medicine, Serum samples, 3. Good health, [SDV] Life Sciences [q-bio], Research Note, Infectious Diseases, Blood, business, Viral load
Abstract

Objectives Molecular assays on nasopharyngeal swabs remain the cornerstone of COVID-19 diagnostics. The high technicalities of nasopharyngeal sampling and molecular assays, as well as scarce resources of reagents, limit our testing capabilities. Several strategies failed, to date, to fully alleviate this testing process (e.g. saliva sampling or antigen testing on nasopharyngeal samples). We assessed the clinical performances of SARS-CoV-2 nucleocapsid antigen (N-antigen) ELISA detection in serum or plasma using the COVID-19 Quantigene® (AAZ, France) assay. Methods Performances were determined on 63 serum samples from 63 non-COVID patients and 227 serum samples (165 patients) from the French COVID and CoV-CONTACT cohorts with RT-PCR-confirmed SARS-CoV-2 infection, including 142 serum samples (114 patients) obtained within 14 days after symptom onset. Results Specificity was 98.4% (95% CI 95.3–100). Sensitivity was 79.3% overall (180/227, 95% CI, 74.0–84.6) and 93.0% (132/142, 95% CI, 88.7–97.2) within 14 days after symptom onset. Ninety-one of the included patients had serum samples and nasopharyngeal swabs collected in the same 24 hr. Among those with high nasopharyngeal viral loads, i.e. Ct value below 30 and 33, only 1/50 and 4/67 tested negative for N-antigenaemia, respectively. Among those with a negative nasopharyngeal RT-PCR, 8/12 presented positive N-antigenaemia; the lower respiratory tract was explored for six of these eight patients, showing positive RT-PCR in five cases. Discussion This is the first evaluation of a commercially available serum N-antigen detection assay. It presents a robust specificity and sensitivity within the first 14 days after symptoms onset. This approach provides a valuable new option for COVID-19 diagnosis, only requiring a blood draw and easily scalable in all clinical laboratories.

Published
2021

221. Valuing genetic and genomic testing in France: current challenges and latest evidence.

Author

Lejeune, Catherine, Amado, Ines F., on behalf of the DEFIDIAG study group, FHU Translad and Aviesan, Humbert-Asensio, Marie-Laure, Binquet, Christine, Deleuze, Jean-Francois, Delmas, Christelle, Dollfus, Hélène, Esperou, Hélène, Faivre, Laurence, Frebourg, Thierry, Gerard, Bénédicte, Guillemin, Francis, Heron, Delphine, Lethimonnier, Franck, Lyonnet, Stanislas, Malle, Carine, Odent, Sylvie, Pélissier, Aurore, and Peyron, Christine

Abstract

High-throughput next-generation sequencing technologies have seen an increase in use in most developed countries. The translation of genomic testing into clinical practice challenges the traditional model of medical care in France and raises numerous medical, legal, ethical, organizational, and financial issues. In order to allow the population to use this revolution to its advantage, France has conceived the French Plan for Genomic Medicine 2025. Its aim is to improve health and quality of life, to organize new pathways of care and counseling, and to make decisions about insurance coverage. It has also been designed to drive innovation and promote economic growth in France by incorporating genomic medicine into the French health care system. These issues can be addressed through evaluations developed to aid the decision-making process in the context of resource scarcity. Health economists can help to resolve these resource allocation challenges by measuring the impact of this technological revolution on patients, caregivers, providers, and the health care system. In this paper, we will review challenges associated with implementing genomic testing in France. One of the pilot studies of the French Plan for Genomic Medicine 2025 will be presented as an illustration of the role of health economists in overcoming some of the challenges of this technological revolution. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

222. Disability progression in multiple sclerosis patients using early first‐line treatments.

Author

Lefort, Mathilde, Vukusic, Sandra, Casey, Romain, Edan, Gilles, Leray, Emmanuelle, Cotton, François, De Sèze, Jérôme, Douek, Pascal, Guillemin, Francis, Laplaud, David, Lebrun‐Frenay, Christine, Pachot, Alexandre, Moreau, Thibault, Olaiz, Javier, Pelletier, Jean, Rigaud‐Bully, Claire, Stankoff, Bruno, Zephir, Hélène, Marignier, Romain, and Debouverie, Marc

Subjects
MULTIPLE sclerosis, GLATIRAMER acetate, DISABILITIES, OLDER patients, TREATMENT delay (Medicine), PEOPLE with disabilities
Abstract

Background and purpose: Therapeutic management of relapsing–remitting multiple sclerosis (RRMS) has evolved towards early treatment. The objective was to assess the impact of early treatment initiation on disability progression amongst RRMS first‐line‐treated patients. Methods: This study included all incident RRMS cases starting interferon or glatiramer acetate for the first time from 1 January 1996 to 31 December 2012 (N = 5279) from 10 MS expert Observatoire Français de la Sclérose en Plaques centres. The delay from treatment start to attaining an irreversible Expanded Disability Status Scale (EDSS) score of 3.0 was compared between the early group (N = 1882; treated within 12 months following MS clinical onset) and the later group using propensity score weighted Kaplan–Meier methods, overall and stratified by age. Results: Overall, the restricted mean time before reaching EDSS 3.0 from treatment start was 11 years and 2 months for patients treated within the year following MS clinical onset and 10 years and 7 months for patients treated later. Thus, early treated patients gained 7 months (95% confidence interval [CI] 4–11 months) in the time to reach EDSS 3.0 compared to patients treated later (treatment start delayed by 28 months). The difference in restricted mean time was respectively 6 months (95% CI 1–10 months) and 14 months (95% CI 4–24 months) in the ≤40 years age group and in the >40 years age group, in favour of the early group. Conclusions: Early treatment initiation resulted in a significant reduction of disability progression amongst patients with RRMS, and also amongst older patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

224. Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group✰

Author

Thomas, Megan, primary, Fraenkel, Liana, additional, Boonen, Annelies, additional, Bansback, Nick, additional, Buchbinder, Rachelle, additional, Marshall, Deborah, additional, Proulx, Laurie, additional, Voshaar, Marieke, additional, Richards, Pamela, additional, Richards, Dawn P., additional, Hiligsmann, Mickael, additional, Guillemin, Francis, additional, Shea, Beverly, additional, Tugwell, Peter, additional, and Hazlewood, Glen, additional

Published
2021
Full Text
View/download PDF

229. Effect of the COVID-19 Outbreak and Lockdown on Mental Health Among Post-Secondary Students in the Grand Est Region of France: Results of the PIMS-Cov19 Study

Author

Baumann, Cédric, primary, Rousseau, Hélène, additional, Tarquinio, Cyril, additional, Batt, Martine, additional, Tarquinio, Pascale, additional, Lebreuilly, Romain, additional, Sorsana, Christine, additional, Legrand, Karine, additional, Guillemin, Francis, additional, and Bourion-Bédès, Stéphanie, additional

Published
2021
Full Text
View/download PDF

231. Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization

Author

Moulin, Charline, primary, Guillemin, Francis, additional, Remen, Thomas, additional, Bouclet, Florian, additional, Hergalant, Sébastien, additional, Quinquenel, Anne, additional, Dartigeas, Caroline, additional, Tausch, Eugen, additional, Lazarian, Grégory, additional, Blanchet, Odile, additional, Lomazzi, Sandra, additional, Chapiro, Elise, additional, Schneider, Christof, additional, Nguyen‐Khac, Florence, additional, Davi, Frédéric, additional, Hunault, Mathilde, additional, Tomowiak, Cécile, additional, Roos‐Weil, Damien, additional, Siebert, Reiner, additional, Thieblemont, Catherine, additional, Cymbalista, Florence, additional, Laribi, Kamel, additional, Béné, Marie‐Christine, additional, Stilgenbauer, Stephan, additional, Guièze, Romain, additional, Feugier, Pierre, additional, and Broséus, Julien, additional

Published
2021
Full Text
View/download PDF

232. Endorsement of the domains of knee and hip osteoarthritis (OA) flare: A report from the OMERACT 2020 inaugural virtual consensus vote from the flares in OA working group

Author

King, Lauren K., primary, Epstein, Jonathan, additional, Cross, Marita, additional, Buzzi, Marie, additional, Buttel, Thomas, additional, Cembalo, Sam Michel, additional, Spitz, Elisabeth, additional, Adams, Cameron L., additional, Adebajo, Adewale, additional, Bennell, Kim, additional, Blanco, Boris, additional, Courage, Uhunmwangho, additional, Décary, Simon, additional, Gill, Michael, additional, Gill, Tiffany K., additional, Hajji, Raouf, additional, Hinman, Rana S., additional, Jones, Allyson, additional, Li, Linda C., additional, Mather, Kate, additional, Mani, Ramakrishnan, additional, Nasef, Samah Ismail, additional, Oo, Win Min, additional, Østerås, Nina, additional, Otobo, Tarimobo M., additional, Ramiro, Sofia, additional, Sharma, Saurab, additional, April, Karine Toupin, additional, Touma, Zahi, additional, Whittaker, Jackie L., additional, Wluka, Anita E., additional, Grosskleg, Shawna, additional, Hunter, David J., additional, Shea, Beverly, additional, Hawker, Gillian A., additional, Callahan, Leigh F., additional, March, Lyn, additional, and Guillemin, Francis, additional

Published
2021
Full Text
View/download PDF

233. OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study

Author

Nielsen, Sabrina Mai, primary, Boers, Maarten, additional, de Wit, Maarten, additional, Shea, Beverly, additional, van der Windt, Danielle A., additional, Reeves, Barnaby C., additional, Beaton, Dorcas, additional, Alten, Rieke, additional, Toupin April, Karine, additional, Boonen, Annelies, additional, Escorpizo, Reuben, additional, Flurey, Caroline, additional, Furst, Daniel E., additional, Guillemin, Francis, additional, Leong, Amye, additional, Pohl, Christoph, additional, Rasmussen, Marianne Uggen, additional, Singh, Jasvinder A., additional, Smolen, Josef S., additional, Strand, Vibeke, additional, Verstappen, Suzanne M.M., additional, Voshaar, Marieke, additional, Woodworth, Thasia G., additional, Ellingsen, Torkell, additional, March, Lyn, additional, Wells, George A., additional, Tugwell, Peter, additional, and Christensen, Robin, additional

Published
2021
Full Text
View/download PDF

234. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach

Author

Toupin-April, Karine, primary, Décary, Simon, additional, de Wit, Maarten, additional, Meara, Alexa, additional, Barton, Jennifer L., additional, Fraenkel, Liana, additional, Li, Linda C., additional, Brooks, Peter, additional, Shea, Beverly, additional, Stacey, Dawn, additional, Légaré, France, additional, Lydiatt, Anne, additional, Hofstetter, Cathie, additional, Proulx, Laurie, additional, Christensen, Robin, additional, Voshaar, Marieke, additional, Suarez-Almazor, Maria E., additional, Boonen, Annelies, additional, Meade, Tanya, additional, March, Lyn, additional, Jull, Janet Elizabeth, additional, Campbell, Willemina, additional, Alten, Rieke, additional, Morgan, Esi M., additional, Kelly, Ayano, additional, Kaufman, Jessica, additional, Hill, Sophie, additional, Maxwell, Lara J., additional, Guillemin, Francis, additional, Beaton, Dorcas, additional, El-Miedany, Yasser, additional, Mittoo, Shikha, additional, Westrich Robertson, Tiffany, additional, Bartlett, Susan J., additional, Singh, Jasvinder A., additional, Mannion, Melissa, additional, Nasef, Samah Ismail, additional, de Souza, Savia, additional, Boel, Anne, additional, Adebajo, Adewale, additional, Arnaud, Laurent, additional, Gill, Tiffany K., additional, Moholt, Ellen, additional, Burt, Jennifer, additional, Jayatilleke, Arundathi, additional, Hmamouchi, Ihsane, additional, Carrott, David, additional, Blanco, Francisco J., additional, Mather, Kate, additional, Maharaj, Ajesh, additional, Sharma, Saurab, additional, Caso, Francesco, additional, Fong, Christopher, additional, Fernandez, Anthony P., additional, Mackie, Sarah, additional, Nikiphorou, Elena, additional, Jones, Allyson, additional, Greer-Smith, Regina, additional, Sloan, Victor S., additional, Akpabio, Akpabio, additional, Strand, Vibeke, additional, Umaefulam, Valerie, additional, Monti, Sara, additional, Melburn, Charmaine, additional, Abaza, Nouran, additional, Schultz, Kirsten, additional, Stones, Simon, additional, Kiwalkar, Sonam, additional, Srinivasalu, Hemalatha, additional, Constien, Deb, additional, King, Lauren K., additional, and Tugwell, Peter, additional

Published
2021
Full Text
View/download PDF

235. Additional file 1 of Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data

Author

Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Moore, Nicholas, and Droz-Perroteau, Cécile

Abstract

Additional file 1: Algorithm for the identification of multiple sclerosis relapses.

Published
2021
Full Text
View/download PDF

236. Additional file 2 of Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data

Author

Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Moore, Nicholas, and Droz-Perroteau, Cécile

Abstract

Additional file 2: Algorithm performance indicators before setting adjustment resulting from expert inputs.

Published
2021
Full Text
View/download PDF

237. Health Literacy throughout adolescence: Invariance and validity study of three measurement scales in the general population

Author

UCL - SSH/IPSY - Psychological Sciences Research Institute, Rouquette, Alexandra, Rigal, Laurent, Mancini, Julien, Guillemin, Francis, Van den Broucke, Stephan, Allaire, Cécile, Azogui-Levy, Sylvie, Ringa, Virginie, Hassler, Christine, UCL - SSH/IPSY - Psychological Sciences Research Institute, Rouquette, Alexandra, Rigal, Laurent, Mancini, Julien, Guillemin, Francis, Van den Broucke, Stephan, Allaire, Cécile, Azogui-Levy, Sylvie, Ringa, Virginie, and Hassler, Christine

Abstract

Objective: To simultaneously investigate the psychometric properties of three recently developed health literacy measurement scales throughout adolescence in the general population. Methods: French versions of the Health Literacy for School-Aged Children (HLSAC, unidimensional) scale, the Health Literacy Assessment Scale for Adolescents (HAS-A, multidimensional) and the 16-item European Health Literacy Survey questionnaire (HLS-EU-Q16, unidimensional) were completed by 1 444 adolescents in 8th, 9th, 11th grade in general school and 11–12th grade in vocational school. Psychometric properties were studied using confirmatory factor analysis, McDonald’s omega coefficient and hypothesis testing. Results: Structural validity was acceptable (HLS-EU-Q16) to good (HAS-A and HLSAC), no measurement invariance issue was found and internal consistency was acceptable for the three scales (0.68–0.84). Convergent validity was low (Pearson correlation coefficients < 0.5) and the only scale for which results were in agreement with a priori hypotheses was the HLSAC. Conclusions: Our results were supportive of the use of HLSAC to assess health literacy during adolescence but the HAS-A, with a slightly better structural validity, can also be promoted due to its three measured dimensions. Practice implications: The use of these scales in practice will help to focus on health literacy, a critical factor for prevention and health promotion in adolescence.

Published
2021

238. EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis

Author

Boonen, Annelies, Putrik, Polina, Marques, Mary Lucy, Alunno, Alessia, Abasolo, Lydia, Beaton, Dorcas, Betteridge, Neil, Björk, Mathilda, Boers, Maarten, Boteva, Boryana, Fautrel, Bruno, Guillemin, Francis, Mateus, Elsa F, Nikiphorou, Elena, Péntek, Márta, Pimentel Santos, Fernando, Severens, Johannes L, Verstappen, Suzanne M M, Walker-Bone, Karen, Wallman, Johan Karlsson, Ter Wee, Marieke M, Westhovens, René, Ramiro, Sofia, Boonen, Annelies, Putrik, Polina, Marques, Mary Lucy, Alunno, Alessia, Abasolo, Lydia, Beaton, Dorcas, Betteridge, Neil, Björk, Mathilda, Boers, Maarten, Boteva, Boryana, Fautrel, Bruno, Guillemin, Francis, Mateus, Elsa F, Nikiphorou, Elena, Péntek, Márta, Pimentel Santos, Fernando, Severens, Johannes L, Verstappen, Suzanne M M, Walker-Bone, Karen, Wallman, Johan Karlsson, Ter Wee, Marieke M, Westhovens, René, and Ramiro, Sofia

Abstract

BACKGROUND: Clinical studies with work participation (WP) as an outcome domain pose particular methodological challenges that hamper interpretation, comparison between studies and meta-analyses. OBJECTIVES: To develop Points to Consider (PtC) for design, analysis and reporting of studies of patients with inflammatory arthritis that include WP as a primary or secondary outcome domain. METHODS: The EULAR Standardised Operating Procedures were followed. A multidisciplinary taskforce with 22 experts including patients with rheumatic diseases, from 10 EULAR countries and Canada, identified methodologic areas of concern. Two systematic literature reviews (SLR) appraised the methodology across these areas. In parallel, two surveys among professional societies and experts outside the taskforce sought for additional methodological areas or existing conducting/reporting recommendations. The taskforce formulated the PtC after presentation of the SLRs and survey results, and discussion. Consensus was obtained through informal voting, with levels of agreement obtained anonymously. RESULTS: Two overarching principles and nine PtC were formulated. The taskforce recommends to align the work-related study objective to the design, duration, and outcome domains/measurement instruments of the study (PtC: 1-3); to identify contextual factors upfront and account for them in analyses (PtC: 4); to account for interdependence of different work outcome domains and for changes in work status over time (PtC: 5-7); to present results as means as well as proportions of patients reaching predefined meaningful categories (PtC: 8) and to explicitly report volumes of productivity loss when costs are an outcome (PtC:9). CONCLUSION: Adherence to these EULAR PtC will improve the methodological quality of studies evaluating WP., Funding: European League Against Rheumatism [EPI021]; NIHR Manchester Biomedical Research CentreNational Institute for Health Research (NIHR); Versus ArthritisVersus Arthritis [20380]

Published
2021
Full Text
View/download PDF

239. Prediction of Outcome and Endovascular Treatment Benefit: Validation and Update of the MR PREDICTS Decision Tool.

Author

Venema, Esmee, Venema, Esmee, Roozenbeek, Bob, Mulder, Maxim JHL, Brown, Scott, Majoie, Charles BLM, Steyerberg, Ewout W, Demchuk, Andrew M, Muir, Keith W, Dávalos, Antoni, Mitchell, Peter J, Bracard, Serge, Berkhemer, Olvert A, Lycklama À Nijeholt, Geert J, van Oostenbrugge, Robert J, Roos, Yvo BWEM, van Zwam, Wim H, van der Lugt, Aad, Hill, Michael D, White, Philip, Campbell, Bruce CV, Guillemin, Francis, Saver, Jeffrey L, Jovin, Tudor G, Goyal, Mayank, Dippel, Diederik WJ, Lingsma, Hester F, HERMES collaborators and MR CLEAN Registry Investigators*, Venema, Esmee, Venema, Esmee, Roozenbeek, Bob, Mulder, Maxim JHL, Brown, Scott, Majoie, Charles BLM, Steyerberg, Ewout W, Demchuk, Andrew M, Muir, Keith W, Dávalos, Antoni, Mitchell, Peter J, Bracard, Serge, Berkhemer, Olvert A, Lycklama À Nijeholt, Geert J, van Oostenbrugge, Robert J, Roos, Yvo BWEM, van Zwam, Wim H, van der Lugt, Aad, Hill, Michael D, White, Philip, Campbell, Bruce CV, Guillemin, Francis, Saver, Jeffrey L, Jovin, Tudor G, Goyal, Mayank, Dippel, Diederik WJ, Lingsma, Hester F, and HERMES collaborators and MR CLEAN Registry Investigators*

Abstract

Background and purposeBenefit of early endovascular treatment (EVT) for ischemic stroke varies considerably among patients. The MR PREDICTS decision tool, derived from MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands), predicts outcome and treatment benefit based on baseline characteristics. Our aim was to externally validate and update MR PREDICTS with data from international trials and daily clinical practice.MethodsWe used individual patient data from 6 randomized controlled trials within the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration to validate the original model. Then, we updated the model and performed a second validation with data from the observational MR CLEAN Registry. Primary outcome was functional independence (defined as modified Rankin Scale score 0–2) 3 months after stroke. Treatment benefit was defined as the difference between the probability of functional independence with and without EVT. Discriminative performance was evaluated using a concordance (C) statistic.ResultsWe included 1242 patients from HERMES (633 assigned to EVT, 609 assigned to control) and 3156 patients from the MR CLEAN Registry (all of whom underwent EVT within 6.5 hours). The C-statistic for functional independence was 0.74 (95% CI, 0.72–0.77) in HERMES and, after model updating, 0.80 (0.78–0.82) in the Registry. Median predicted treatment benefit of routinely treated patients (Registry) was 10.3% (interquartile range, 5.8%–14.4%). Patients with low (<1%) predicted treatment benefit (n=135/3156 [4.3%]) had low rates of functional independence, irrespective of reperfusion status, suggesting potential absence of treatment benefit. The updated model was made available online for clinicians and researchers at www.mrpredicts.com.ConclusionsBecause of the substantial treatment effect and small potential harm of EVT, most patients arriving within 6 hours

Published
2021

240. Comparing the Prognostic Impact of Age and Baseline National Institutes of Health Stroke Scale in Acute Stroke due to Large Vessel Occlusion

Author

Ospel, Johanna Maria, Brown, Scott, Kappelhof, Manon, van Zwam, Wim, Jovin, Tudor, Roy, Daniel, Campbell, Bruce C., Mitchell, Peter, Roos, Yvo, Guillemin, Francis, Buck, Brian, Muir, Keith, Bracard, Serge, White, Phil, de Rochemont, Richard du Mesnil, Goyal, Mayank, HERMES Investigators, Ospel, Johanna Maria, Brown, Scott, Kappelhof, Manon, van Zwam, Wim, Jovin, Tudor, Roy, Daniel, Campbell, Bruce C., Mitchell, Peter, Roos, Yvo, Guillemin, Francis, Buck, Brian, Muir, Keith, Bracard, Serge, White, Phil, de Rochemont, Richard du Mesnil, Goyal, Mayank, and HERMES Investigators

Abstract

Background and Purpose: Little is known about the combined effect of age and National Institutes of Health Stroke Scale (NIHSS) in endovascular treatment (EVT) for acute ischemic stroke due to large vessel occlusion, and it is not clear how the effects of baseline age and NIHSS on outcome compare to each other. The previously described Stroke Prognostication Using Age and NIHSS (SPAN) index adds up NIHSS and age to a 1:1 combined prognostic index. We added a weighting factor to the NIHSS/age SPAN index to compare the relative prognostic impact of NIHSS and age and assessed EVT effect based on weighted age and NIHSS. Methods: We performed adjusted logistic regression with good outcome (90-day modified Rankin Scale score 0-2) as primary outcome. From this model, the coefficients for NIHSS and age were obtained. The ratio between the NIHSS and age coefficients was calculated to determine a weighted SPAN index. We obtained adjusted effect size estimates for EVT in patient subgroups defined by weighted SPAN increments of 3, to evaluate potential changes in treatment effect. Results: We included 1750/1766 patients from the HERMES collaboration (Highly Effective Reperfusion Using Multiple Endovascular Devices) with available age and NIHSS data. Median NIHSS was 17 (interquartile range, 13-21), and median age was 68 (interquartile range, 57-76). Good outcome was achieved by 682/1743 (39%) patients. The NIHSS/age effect coefficient ratio was ([-0.0032]/[-0.111])=3.4, which was rounded to 3, resulting in a weighted SPAN index defined as ([3xNIHSS]+age). Cumulative EVT effect size estimates across weighted SPAN subgroups consistently favored EVT, with a number needed to treat ranging from 5.3 to 8.7. Conclusions: The impact on chance of good outcome of a 1-point increase in NIHSS roughly corresponded to a 3-year increase in patient age. EVT was beneficial across all weighted age/NIHSS subgroups.

Published
2021

241. Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke A Meta-analysis of Individual Patient Data From 7 Randomized Clinical Trials

Author

Almekhlafi, Mohammed A., Goyal, Mayank, Dippel, Diederik W. J., Majoie, Charles B. L. M., Campbell, Bruce C. V., Muir, Keith W., Demchuk, Andrew M., Bracard, Serge, Guillemin, Francis, Jovin, Tudor G., Mitchell, Peter, White, Philip, Hill, Michael D., Brown, Scott, Saver, Jeffrey L., HERMES Trialists Collaboration, van Zwam, Wim, van Oostenbrugge, Robert Jan, Almekhlafi, Mohammed A., Goyal, Mayank, Dippel, Diederik W. J., Majoie, Charles B. L. M., Campbell, Bruce C. V., Muir, Keith W., Demchuk, Andrew M., Bracard, Serge, Guillemin, Francis, Jovin, Tudor G., Mitchell, Peter, White, Philip, Hill, Michael D., Brown, Scott, Saver, Jeffrey L., HERMES Trialists Collaboration, van Zwam, Wim, and van Oostenbrugge, Robert Jan

Abstract

This meta-analysis evaluates outcomes along the full health-related quality-of-life range associated with time to endovascular thrombectomy in patients with ischemic stroke.Question What are the lifetime consequences associated with care process delays in patients with ischemic stroke who are treated with endovascular thrombectomy? Findings In this meta-analysis of pooled individual patient data from 406 adults in 7 randomized trials, delays in delivering endovascular thrombectomy were associated with marked reductions in healthy life-years after treatment. In the time interval from hospital arrival to endovascular procedure start, every 1 second of delay was associated with loss of 2.2 hours of healthy life. Meaning In this study, care delays in delivering endovascular thrombectomy to ischemic stroke patients were associated with substantial losses of healthy life-years; health care organization and workflow optimization should be a priority to facilitate faster reperfusion for acute stroke patients.Importance The benefits of endovascular thrombectomy (EVT) are time dependent. Prior studies may have underestimated the time-benefit association because time of onset is imprecisely known. Objective To assess the lifetime outcomes associated with speed of endovascular thrombectomy in patients with acute ischemic stroke due to large-vessel occlusion (LVO). Data Sources PubMed was searched for randomized clinical trials of stent retriever thrombectomy devices vs medical therapy in patients with anterior circulation LVO within 12 hours of last known well time, and for which a peer-reviewed, complete primary results article was published by August 1, 2020. Study Selection All randomized clinical trials of stent retriever thrombectomy devices vs medical therapy in patients with anterior circulation LVO within 12 hours of last known well time were included. Data Extraction/Synthesis Patient-level data regarding presenting clinical and imaging features and fu

Published
2021

242. Prediction of Outcome and Endovascular Treatment Benefit:Validation and Update of the MR PREDICTS Decision Tool

Author

Venema, Esmee, Roozenbeek, Bob, Mulder, Maxim J.H.L., Brown, Scott, Majoie, Charles B.L.M., Steyerberg, Ewout W., Demchuk, Andrew M., Muir, Keith W., Dávalos, Antoni, Mitchell, Peter J., Bracard, Serge, Berkhemer, Olvert A., Lycklama À Nijeholt, Geert J., Van Oostenbrugge, Robert J., Roos, Yvo B.W.E.M., Van Zwam, Wim H., Van Der Lugt, Aad, Hill, Michael D., White, Philip, Campbell, Bruce C.V., Guillemin, Francis, Saver, Jeffrey L., Jovin, Tudor G., Goyal, Mayank, Dippel, Diederik W.J., Lingsma, Hester F., Venema, Esmee, Roozenbeek, Bob, Mulder, Maxim J.H.L., Brown, Scott, Majoie, Charles B.L.M., Steyerberg, Ewout W., Demchuk, Andrew M., Muir, Keith W., Dávalos, Antoni, Mitchell, Peter J., Bracard, Serge, Berkhemer, Olvert A., Lycklama À Nijeholt, Geert J., Van Oostenbrugge, Robert J., Roos, Yvo B.W.E.M., Van Zwam, Wim H., Van Der Lugt, Aad, Hill, Michael D., White, Philip, Campbell, Bruce C.V., Guillemin, Francis, Saver, Jeffrey L., Jovin, Tudor G., Goyal, Mayank, Dippel, Diederik W.J., and Lingsma, Hester F.

Abstract

Background and Purpose: Benefit of early endovascular treatment (EVT) for ischemic stroke varies considerably among patients. The MR PREDICTS decision tool, derived from MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands), predicts outcome and treatment benefit based on baseline characteristics. Our aim was to externally validate and update MR PREDICTS with data from international trials and daily clinical practice. Methods: We used individual patient data from 6 randomized controlled trials within the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration to validate the original model. Then, we updated the model and performed a second validation with data from the observational MR CLEAN Registry. Primary outcome was functional independence (defined as modified Rankin Scale score 0-2) 3 months after stroke. Treatment benefit was defined as the difference between the probability of functional independence with and without EVT. Discriminative performance was evaluated using a concordance (C) statistic. Results: We included 1242 patients from HERMES (633 assigned to EVT, 609 assigned to control) and 3156 patients from the MR CLEAN Registry (all of whom underwent EVT within 6.5 hours). The C-statistic for functional independence was 0.74 (95% CI, 0.72-0.77) in HERMES and, after model updating, 0.80 (0.78-0.82) in the Registry. Median predicted treatment benefit of routinely treated patients (Registry) was 10.3% (interquartile range, 5.8%-14.4%). Patients with low (<1%) predicted treatment benefit (n=135/3156 [4.3%]) had low rates of functional independence, irrespective of reperfusion status, suggesting potential absence of treatment benefit. The updated model was made available online for clinicians and researchers at www.mrpredicts.com. Conclusions: Because of the substantial treatment effect and small potential harm of EVT, most patients arriving w

Published
2021

243. EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)

Author

Costantino, Félicie, Carmona, Loreto, Boers, Maarten, Backhaus, Marina, Balint, Peter V., Bruyn, George A., Christensen, Robin, Conaghan, Philip G., Ferreira, Ricardo J.O., Garrido-Castro, Juan Luis, Guillemin, Francis, Hammer, Hilde Berner, van der Heijde, Désirée, Iagnocco, Annamaria, Kortekaas, Marion C., Landewé, Robert B.M., Mandl, Peter, Naredo, Esperanza, Schmidt, Wolfgang A., Terslev, Lene, Terwee, Caroline B., Thiele, Ralf, D'Agostino, Maria Antonietta, Costantino, Félicie, Carmona, Loreto, Boers, Maarten, Backhaus, Marina, Balint, Peter V., Bruyn, George A., Christensen, Robin, Conaghan, Philip G., Ferreira, Ricardo J.O., Garrido-Castro, Juan Luis, Guillemin, Francis, Hammer, Hilde Berner, van der Heijde, Désirée, Iagnocco, Annamaria, Kortekaas, Marion C., Landewé, Robert B.M., Mandl, Peter, Naredo, Esperanza, Schmidt, Wolfgang A., Terslev, Lene, Terwee, Caroline B., Thiele, Ralf, and D'Agostino, Maria Antonietta

Abstract

To produce European League Against Rheumatism (EULAR) recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Based on the literature reviews and expert opinion (through Delphi surveys), a taskforce of 23 members (12 experts in ultrasound in RMDs, 9 in methodology and biostatistics together with a patient research partner and a health professional in rheumatology) developed a checklist of items to be reported in every RMD study using ultrasound. This checklist was further refined by involving a panel of 79 external experts (musculoskeletal imaging experts, methodologists, journal editors), who evaluated its comprehensibility, feasibility and comprehensiveness. Agreement on each proposed item was assessed with an 11-point Likert scale, grading from 0 (total disagreement) to 10 (full agreement). Two face-to-face meetings, as well as two Delphi rounds of voting, resulted in a final checklist of 23 items, including a glossary of terminology. Twenty-one of these were considered ‘mandatory’ items to be reported in every study (such as blinding, development of scoring systems, definition of target pathologies) and 2 ‘optional’ to be reported only if applicable, such as possible confounding factors (ie, ambient conditions) or experience of the sonographers. An EULAR taskforce developed a checklist to ensure transparent and comprehensive reporting of aspects concerning research and procedures that need to be presented in studies using ultrasound in RMDs. This checklist, if widely adopted by authors and editors, will greatly improve the interpretability of study development and results, including the assessment of validity, generalisability and applicability.

Published
2021

244. Endovascular Treatment Effect Diminishes with Increasing Thrombus Perviousness:Pooled Data from 7 Trials on Acute Ischemic Stroke

Author

Kappelhof, Manon, Tolhuisen, Manon L., Treurniet, Kilian M., Dutra, Bruna G., Alves, Heitor, Zhang, Guang, Brown, Scott, Muir, Keith W., Davalos, Antoni, Roos, Yvo B.W.E.M., Saver, Jeffrey L., Demchuk, Andrew M., Jovin, Tudor G., Bracard, Serge, Campbell, Bruce C.V., Van Der Lugt, Aad, Guillemin, Francis, White, Philip, Hill, Michael D., Dippel, Diederik W.J., Mitchell, Peter J., Goyal, Mayank, Marquering, Henk A., Majoie, Charles B.L.M., Kappelhof, Manon, Tolhuisen, Manon L., Treurniet, Kilian M., Dutra, Bruna G., Alves, Heitor, Zhang, Guang, Brown, Scott, Muir, Keith W., Davalos, Antoni, Roos, Yvo B.W.E.M., Saver, Jeffrey L., Demchuk, Andrew M., Jovin, Tudor G., Bracard, Serge, Campbell, Bruce C.V., Van Der Lugt, Aad, Guillemin, Francis, White, Philip, Hill, Michael D., Dippel, Diederik W.J., Mitchell, Peter J., Goyal, Mayank, Marquering, Henk A., and Majoie, Charles B.L.M.

Abstract

Background and Purpose: Thrombus perviousness estimates residual flow along a thrombus in acute ischemic stroke, based on radiological images, and may influence the benefit of endovascular treatment for acute ischemic stroke. We aimed to investigate potential endovascular treatment (EVT) effect modification by thrombus perviousness. Methods: We included 443 patients with thin-slice imaging available, out of 1766 patients from the pooled HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke trials) data set of 7 randomized trials on EVT in the early window (most within 8 hours). Control arm patients (n=233) received intravenous alteplase if eligible (212/233; 91%). Intervention arm patients (n=210) received additional EVT (prior alteplase in 178/210; 85%). Perviousness was quantified by thrombus attenuation increase on admission computed tomography angiography compared with noncontrast computed tomography. Multivariable regression analyses were performed including multiplicative interaction terms between thrombus attenuation increase and treatment allocation. In case of significant interaction, subgroup analyses by treatment arm were performed. Our primary outcome was 90-day functional outcome (modified Rankin Scale score), resulting in an adjusted common odds ratio for a one-step shift towards improved outcome. Secondary outcomes were mortality, successful reperfusion (extended Thrombolysis in Cerebral Infarction score, 2B-3), and follow-up infarct volume (in mL). Results: Increased perviousness was associated with improved functional outcome. After adding a multiplicative term of thrombus attenuation increase and treatment allocation, model fit improved significantly (P=0.03), indicating interaction between perviousness and EVT benefit. Control arm patients showed significantly better outcomes with increased perviousness (adjusted common odds ratio, 1.2 [95% CI, 1.1-1.3]). In the EVT arm, no significant association was found (adjusted co

Published
2021

249. Clinico-Biological, Molecular and Prognostic Features of Patients with Diffuse Large B-Cell Lymphoma-Variant of Richter Syndrome: A Multicenter Retrospective Study of the French Innovative Leukemia Organization

Author

Moulin, Charline, Guillemin, Francis, Remen, Thomas, Bouclet, Florian, Augé, Hélène, Quinquenel, Anne, Dartigeas, Caroline, Morizot, Romain, Lomazzi, Sandra, Busby, Hélène, Hergalant, Sebastien, Tausch, Eugen, Tomowiak, Cécile, Leblond, Veronique, Thieblemont, Catherine, Cymbalista, Florence, Laribi, Kamel, Bene, Marie C, Stilgenbauer, Stephan, Guieze, Romain, Feugier, Pierre, and Broséus, Julien

Published
2020
Full Text
View/download PDF

250. Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: the EUMUSC.NET project

Author

Moe, Rikke H, Petersson, Ingemar F, Carmona, Loreto, Greiff, Rolf, Guillemin, Francis, Udrea, Gabriela, Loza, Estibaliz, Stoffer, Michaela A, de Wit, Maarten, Wiek, Dieter, Vliet Vlieland, Theodora, Woolf, Anthony D, Uhlig, Till, Edwards, Katie, Howarth, Jim, Boonen, Annelies, Anhalt, Babette, Dougados, Maxime, Smolen, Josef, and A Stamm, Tanja

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results